News | August 12, 2022
Hikal shows 17% degrowth in Q1 FY23
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
The company plans to execute both these tenders at their API manufacturing unit located at Savli, Gujarat, India.
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
Subscribe To Our Newsletter & Stay Updated
